Evidence for a two-stage disability progression in multiple sclerosis

Brain

Volumn 133, Issue 7, 2010, Pages 1900-1913

  Leray, Emmanuelle ^a   Yaouanq, Jacqueline ^a   Le Page, Emmanuelle ^a   Coustans, Marc ^a   Laplaud, David ^a   Oger, Joël ^a,b   Edan, Gilles ^a,c  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITÉ DE RENNES 1   (France)

Author keywords

age; course; disability progression; multiple sclerosis; prognosis

Indexed keywords

ADULT; AGED; ARTICLE; AXONAL INJURY; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; INFLAMMATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGE FACTORS; AGED; DATABASES, FACTUAL; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 77954382272     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq076     Document Type: Article

References (48)

1. CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, et al. Alemtuzumab vs Interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-1801
2. Charcot JM. Leçons sur les maladies du système nerveux faites à la Salpétrière. Paris: A Delahaye; 1880.
3. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-687
4. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108.
5. Compston A. Making progress on the natural history of multiple sclerosis. Brain 2006; 129: 561-563
6. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1520-1527
7. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006a; 129: 606-616 (Pubitemid 43278223)
8. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006b; 129: 595-605.
9. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability: an amnesic process. Brain 2003; 126: 770-782
10. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438
11. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671-676
12. Confavreux C, Ritleng C, Debouverie M, Durand-Dubief F, Marignier R, Androdias G, et al. Defining the natural history of MS: the need for complete data and rigorous definitions. Answer to Dr Tremlett et al. Mult Scler 2008; 14: 1144-1147
13. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geaogra-phically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122: 625-639 (Pubitemid 29158771)
14. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972; 34: 187-220.
15. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol 2008; 15: 916-921
16. Ebers GC. Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005; 252(Suppl 3): iii15-iii20.
17. Fisnicu LK, Brex PA, Altmann TR, Riskiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20 year follow-up of patients with relapse onset of MS. Brain 2008; 131: 808-817
18. Frischer J, Brasmow S, Lucchinetti C, Raushka H, Schimdbauer M, Laursen H, et al. The relationship between inflammation and neuro-degeneration in multiple sclerosis. Brain 2009; 132: 1175-1189
19. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular Interferon Beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294
20. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sü tlas N, Agaoglu J, et al. Survival and predictors of disability in Turkish MS patients. Neurology 1998; 51: 765-772
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
22. Kappos L, Freedman M, Polman C, Edan G, Hartung P, Miller DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389-397
23. Koch M, Mostert J, Heersema D, De Keyser J. Progression in multiple sclerosis: further evidence of an age dependant process. J Neurol Sci 2007; 255: 35-41.
24. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically bases study. 9: Observations on the progressive phase of the disease. Brain 2006; 129: 584-594
25. Kurtzke JF. On the evaluation of disability in multiple sclerosis. Neurology 1961; 11: 686-694
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452
27. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-2712
28. Leray E, Morrissey S, Yaouanq J, Coustans M, Le Page E, Chaperon J, et al. Long term survival of patients with multiple sclerosis in West France. Mult Scler 2007; 13: 865-874
29. Li DK, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006; 66: 1384-1389
30. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-911
31. Lublin FD, Baier M, Cutter G. Effect of relapse on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-1532
32. Panitch H, Miller A, Paty D, Weinshenker B. North American Study Group on interferon beta 1b in secondary progressive MS. Neurology 2004; 63: 1788-1795
33. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular references to its course and prognosis. Brain 1990; 113: 1597-1628
34. Poser CM, Paty DW, Scheinberg L, Mc Donald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231
35. PRISMS Study Group (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis). Randomised double-blind placebo controlled study of interferon beta-1a in relapsing-remit-ting multiple sclerosis. Lancet 1998; 352: 1498-1504
36. Rice GP, Filippi M, Comi G. Cladribine and progressive multiple sclerosis: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145-1155
37. Runmarker B, Andersen O. Pronostic factors in a multiple sclerosis incidence cohort with twenty five years of follow-up. Brain 1993; 116: 117-134
38. SPECTRIMS Study Group (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon beta-1a in MS). Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 2001; 56: 1496-1504
39. Stankoff B, Mrejen S, Tourbah A, Fontaine B, Lyon-Caen O, Lubetzki C, et al. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology 2007; 68: 779-781
40. Statistical Package for Social Science [program]. Chicago: SPSS; 2002.
41. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transaction in the lesion of multiple sclerosis. N Engl J Med 1998; 338: 278-285
42. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66: 172-177
43. Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol 2009; 256: 374-381
44. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73: 1616-1623
45. Weiner H. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65: 239-248
46. Weinshenker BG, Bass B, Rice GP, Noseworthy JH, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989a; 112: 133-146 (Pubitemid 19056478)
47. Weinshenker BG, Bass B, Rice GP, Noseworthy JH, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989b; 112: 1419-1428 (Pubitemid 20024212)
48. Young PY, Lederer C, Eder K, Daumer M, Neiss A, Polman C, et al. Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology 2006; 67: 804-808